Preventive Role of Renal Kallikrein-Kinin System in the Early Phase of Hypertension andDevelopment of New Antihypertensive Drugs

Advances in Pharmacology

Volumn 44, Issue C, 1998, Pages 147-224

  Katori, Makoto ^a   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; KALLIKREIN; KININ;

ANIMAL; DRUG DESIGN; HUMAN; HYPERTENSION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; URINE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; HUMANS; HYPERTENSION; KALLIKREINS; KIDNEY; KININS;

EID: 0031611603     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60127-1     Document Type: Chapter

References (363)

1. Abe K., Seino M., Otsuka Y., and Yoshinaga K. Urinary kallikrein excretion and sodium metabolism in human hypertension. In: Pisano J.J., and Austen K.F. (Eds). Chemistry and Biology of the Kallikrein-Kinin System in Health and Disease (1977), Fogarty International Center Proc., Washington, DC. 411-414
2. Abe K., Yasujima M., Irokawa N., Seino M., Chiba S., Sakurai Y., Sato M., Imai Y., Saito K., Ito T., Haruyama T., Otsuka Y., and Yoshinaga K. The role of intrarenal vasoactive substances in the pathogenesis of essential hypertension. Clin. Sci. Mol. Med. 55 (1978) 363s-366s
3. Abelous J.E., and Bardier E. Les substance hypotensive de ľurine humaine normale. Crit. Rev. Soc. Biol. 66 (1909) 511
4. Adachi K., Majima M., Katori M., and Nishijima M. Oxytocin-induced natriuresis mediated by the renal kallikrein-kinin system in anesthetized male rats. Jpn. J. Pharmacol. 67 (1995) 243-252
5. Ader J.-L., Pollock D.M., Butterfield M.I., and Arendshorst W.J. Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am. J. Physiol. 248 (1985) F396-F403
6. Ader J.-L., Tran-Van T., and Praddaude F. Reduced urinary kallikrein activity in rats developing spontaneous hypertension. Am. J. Physiol. 252 (1987) F964-F969
7. Adetuyibi A., and Mills I.H. Relation between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man. Lancet ii (1972) 203-207
8. Alla S.A., Buschko J., Qitterer U., Maidhof A., Haasemann M., Breipohl G., Knolle J., and Mueller-Esterl W. Structural features of the human bradykinin Breceptor probed by agonist, antagonists and anti-iodotypic antibodies. J. Biol. Chem. 268 (1993) 17277-17285
9. Alla S.A., Qitterer U., Grigoriev S., Maidhof A., Haasemann M., Jarnagin K., and Mueller-Esterl W. Extracellular domains of the bradykinin Breceptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J. Biol. Chem. 271 (1996) 1748-1755
10. Amico J.A., Seif S.M., and Robinson A.G. Oxytocin in human plasma: Correlation with neurophysin and stimulation with estrogen. J. Clin. Endocrinol. Metab. 52 (1981) 988-993
11. Arbeit L.A., and Serra S.R. Decreased total and active urinary kallikrein in normotensive Dahl salt susceptible rats. Kidney Int. 28 (1985) 440-446
12. August J.T., Nelson D.H., and Thorn G.W. Response of normal subjects to large amounts of aldosterone. J. Clin. Invest. 38 (1958) 1549-1555
13. Balment R.J., Brimble M.J., and Forsling M.L. Release of oxytocin induced by salt loading and its influence on renal excretion in the male rat. J. Physiol. (Lond.) 308 (1980) 439-449
14. Balment R.J., Brimble M.J., Forsling M.L., and Musabayane C.T. The influence of neurohypophysial hormones on renal function in the acutely hypophysectomized rat. J. Physiol. (Lond.) 3381 (1986) 439-451
15. Barraclough M.A., and Mills I.H. Effects of bradykinin on renal function. Clin. Sci. 28 (1965) 199-206
16. Bascands J.L., Girolami J.-P., Pecher C., Moatti J.-P., Manuel Y., and Sue J.M. Compared effects of a low and a high sodium diet on the renal and urinary concentration and activity of kallikrein in normal rats. J. Hypertens. 5 (1987) 311-315
17. Beierwalter W.H., Arendshorst W.J., and Klemmer P.J. Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4 (1982) 908-915
18. Berg T., Bradshaw R.A., Carretero O.A., Chao J., Chao L., Clements J.A., Fahnesto Gauthier F., MacDonald R.J., Margolius H.S., Morris B.J., Richards R.I., and Scicli A.G. A common nomenclature for members of the tissue (glandular) kallikrein gene families.". Agents Actions 38 (1992) 19-25
19. Berk B.C., Vallega G., Muslin A.J., Gordon H.M., Canessa M., and Alexander R.W. Spontaneously hypertensive rat vascular smooth muscle cells in culture exhibit increased growth and Na+/H+ exchange. J. Clin. Invest. 83 (1989) 822-829
20. Berry T.D., Hasstedt S.J., Hunt S.C., Wu L.L., Smith J.B., Ash K.O., Kuida H., and Williams R.R. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 3 (1989) 3-8
21. Berry C.A., and Rector F.C.J. Renal transport of glucose, amino acids, sodium, chloride and water. The Kidney. 1 (1991), W. B. Saunders, Philadelphia. 250-251
22. Bevan D.R., MacFarlane N.A.A., and Mills I.H. The dependence of urinary kallikrein excretion on renal artery pressure. J. Physiol. (Lond.) 241 (1974) 34P-35P
23. Bevan E.G., Connell J.M.C., Doyle J., Carmichael H.A., Davies D.L., Lorimer A.R., and Mclnnes G.T. Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension. J. Hypertens. 10 (1992) 607-613
24. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev. 44 (1992) 1-80
25. Bianchi G., Fox U., and Imbasciati E. The development of a new strain of spontaneously hypertensive rats. Life Sci. 14 (1974) 339-347
26. Bianchi G.P., Fox U., Di Francesco G.F., Giovanetti M., and Bagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. Clin. Sci. Mol. Med. 47 (1974) 435-448
27. Bianchi G.P., Baer G., Fox U., Duzzi L., Pagetti D., and Giovanetti M. Changes in renin, water balance, and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ. Res. 36 (1975) 1-153 1-161
28. Bianchi G., Ferrari P., Trizio D., Ferrandi M., Torielli L., Barber B.R., and Poli E. Red blood cell abnormalities and spontaneous hypertension in the rat. A genetically determined link. Hypertension 7 (1985) 319-325
29. Bianchi G., Tripodi G., Casari G., Salardi S., Barber B.R., Garcia R., Leoni P., Torielli L., Cusi D., Ferrandi M., Pinna L.A., Baralle F.E., and Ferrari P. Two point mutations within the adducin genes are involved in blood pressure variation. Proc. Natl. Acad. Sci. USA 91 (1994) 3999-4003
30. 2+ and nitric oxide in bradykinin-stimulated vascular endothelial cells. Circ. Res. 76 (1995) 922-924
31. Bönner G., Rasher W., Speck G., Marin-Grez J., and Gross F. The renal kallikrein-kinin system in Brattleboro rats with hereditary hypothalamic diabetes inspidus. Acta Endocrinol. 98 (1981) 35-42
32. Bönner G., Schwertschlag U., Martin-Grez M., and Gross F. Effect of changes in perfusion pressure on urinary kallikrein in the isolated perfused rat kidney. Renal Physiol. 6 (1983) 288-294
33. Bönner G., Preis S., Schunk U., Toussaint C., and Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J. Cardiovasc. Pharmacol. 15 Suppl. 6 (1990) S46-S56
34. Bönner G., Thieven B., Ruetten H., Chrosch R., and Krone W. Renal lcallikrein is a determinant of salt sensitivity. J. Hypertens. 11 Suppl. 5 (1993) S210-S211
35. Borkowski J.A., Ransom R.W., Seabrook G.R., Trumbauer M., Chen H., Hill R.G., Strader C.D., and Hess J.R. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. 270 (1995) 13706-13710
36. 2 receptor antagonism on the hypotensive effects of ACE inhibition. Br. J. Pharmacol. 113 (1994) 717-722
37. Brimble M.J., Balment R.J., Smith C.P., Windle R.J., and Forsling M.L. Influence of oxytocin on sodium excretion in the anaesthetized Brattleboro rat. J. Endocrinol. 129 (1991) 49-54
38. Brooks F.P., and Pickford M. The effects of posterior pituitary hormones on the excretion of electrolytes in dogs. J. Physiol. (Lond.) 142 (1958) 468-493
39. Burnier M., Porcher M., Ganslmayer M., Nussberger J., Kosoglou T., Waeber B., and Brunner H. Naturiuretic effects of SCH 34826, an orally active neutral endopeptidase (NEP) inhibitor: Results of a randomized four way crossover study in salt loaded volunteers. J. Hypertens. 8 Suppl. 3 (1990) s9
40. Carone F.A., Pullman T.N., Oparil S., and Nakamura S. Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubules. Am. J. Physiol. 230 (1976) 1420-1424
41. Carretero O.A., Oza N.B., and Schork A. Renal kallikrein, plasma renin, and plasma aldosterone in renal hypertension. Acta Physiol, hat. Am. 24 (1974) 448-452
42. Carretero O.A., Polomski C., Hampton A., and Scicli A.G. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin. Exp. Pharmacol. Physiol. 3 Suppl. 5 (1976) 55-59
43. Carretero O.A., and Scicli A.G. The kallikrein-kinin system in human and in experimental hypertension. Klin. Wochenschr. 56 Suppl. 5 (1978) 113-125
44. Carretero O.A., Amin V.M., Ocholik T., Scicli A.G., and Koch J. Urinary kallikrein in rats bred to susceptibility and resistance to the hypertensive effect of salt: A new radioimmunoassay for its direct determination. Circ. Res. 42 (1978) 727-731
45. Carretero O.A., and Scicli A.G. The renal kallikrein-kinin system. Am. J. Physiol. 238 (1980) F247-F255
46. Carretero O.A., and Scicli A.G. Kinins as regulators of blood flow and blood pressure. Hypertension: Pathophysiology, Diagnosis, and Management (1990), Raven Press, New York. 805-817
47. Casari G., Barlassina C., Cusi D., Zagato L., Muirhead R., Righetti M., Nembri P., Amar K., Gatti M., Macciardi F., Binelli G., and Bianchi G. Association of the α-adducin locus with essential hypertension. Hypertension 25 (1995) 320-326
48. Cattran D.C., Greenwood C., and Ritchie S. Long term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am. J. Kidney Dis. 23 (1994) 247-254
49. Cavero P.G., Margulies K.B., Winaver J., Seymour A.A., Delaney N.G., and Burnett Jr. J.C. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 82 (1990) 196-201
50. Chai K.X., Ni A., Wang D., Ward D.C., Chao J., and Chao L. Genomic DNA sequence, expression, and chromosomal localization of the human Bbradykinin receptor gene BDKRB1. Genomics 31 (1996) 51-57
51. Chan W.Y., and Sawyer W.H. Saluretic action of neurohypophysial peptides in conscious dogs. Am. J. Physiol. 201 (1958) 799-803
52. Chan W.Y. Effect of neurophysial hormones and their deamino analogue on renal excretion of Na, K and water in rats. Endocrinology 77 (1961) 1097-1104
53. Chan W.Y. Renal prostaglandins and natriuretic action of oxytocin and vasopressin in rats. J. Pharmacol. Exp. Ther. 246 (1988) 603-609
54. Chang E., and Perlman A.J. Multiple hormones regulate angiotensinogen messenger ribonucleic acid levels in a rat hepatoma cell line. Endocrinology 121 (1987) 513-519
55. Chao J., and Chao L. A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J. Hypertens. 6 (1988) 551-557
56. Chao J., Swain C., Chao S., Xiong W., and Chao L. Tissue distribution and kininogen gene expression after acute-phase inflammation. Biochim. Biophys. Acta 964 (1988) 329-339
57. Chao J., Chai K.X., Chen L.M., Xiong W., Chao S., Woodley-Miller C., Wang L., Lu H.S., and Chao L. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J. Biol. Chem. 265 (1990) 16394-16401
58. Chao J., and Chao L. Biochemistry, regulation and potential function of kallistatin. Biol. Chem. Hoppe-Seyler 376 (1995) 705-713
59. Chao J., and Chao L. Functional analysis of human tissue kallikrein in transgenic mouse model. II. Hypertension 27 (1996) 491-494
60. Chen K., and Zimmerman B.G. Comparison of renal hemodynamic effect of captopril: Possible role of kinins. J. Pharmacol. Exp. Ther. 270 (1994) 491-497
61. Chen L.-M., Song Q., Chao L., and Chao J. Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int. 48 (1995) 690-697
62. Chiu P.J.S., Tetzloff G., Romano M.T., Foster C.J., and Sybertz E.J. Influence of C-ANP receptor and neutral endopeptidase on pharmacokinetics of ANF in rats. Am. J. Physiol. 260 (1991) R208-R216
63. Churchill P.C., Churchill M.C., Bidani A.K., and Rabito S.F. Kallikrein excretion in Dahl salt-sensitive and salt-resistant rats with native and transplanted kidneys. Am. J. Physiol. 269 (1995) F710-F717
64. Clements J., Mukhtar A., Ehrlich A., and Fuller P. A reevaluation of the tissue-specific pattern of expression of the rat kallikrein gene family. Agents Actions 38 Suppl. 5 (1992) 34-41
65. Colman R.W., Bagdasarian A., Talamo R.C., Scott C.F., Seavey M., Guimaraes J.A., Pierce J.V., and Kaplan A.P. Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 56 (1975) 1650-1662
66. Colman R.W., and Wong P.Y. Kallikrein-kinin system in pathologic conditions. Bradykinin, kallidin and kallikrein. 25 (1979), Springer-Verlag, New York. 569-607
67. Colman R.W. Inhibitory and antiadhesive properties of human kininogens. Immunopharmacology 32 (1996) 9-18
68. Conrad K.P., Gellai M., North W.G., and Valtin H. Influence of oxytocin on renal hemodynamics and electrolyte and water excretion. Am. J. Physiol. 251 (1986) F290-F296
69. Corvol P. Role of the renin-angiotensin-aldosterone system in blood pressure regulation and in human hypertension: New sights from molecular genetics. Recent Prog. Horm. Res. 50 (1995) 287-308
70. Croxatto H.R., Huidobro F., Rojas M., Roblero J., and Albertini R. The effect of water, sodium overloading and diuretics upon urinary kallikrein. Kinins: Pharmacodynamics and Biological Roles (1975), Plenum Press, New York. 361-373
71. Cumming A.D., Walsh T., Wojtacha D., Fleming S., Thomson D., and Jenkins D.A.S. Expression of tissue kallikrein in human kidney. Clin. Sci. 87 (1994) 5-11
72. - cotransport and kidney function in essential hypertension. J. Hypertens. 11 (1993) 805-813
73. Dahl L.K., Heine M., and Tassinari L. Effects of chronic excess salt ingestion. Evidence that genetic factors play an important role in susceptibility to experimental hypertension. J. Exp. Med. 115 (1962) 1173-1190
74. Dahl L.K., Heine M., and Tassinari L. Role of genetic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature 194 (1962) 480-482
75. Dahl L.K., Heine M., and Tassinari L. Effects of chronic excess salt ingestion. Role of genetic factors in both DOCA-salt and renal hypertension. J. Exp. Med. 118 (1963) 605-617
76. Dahl L.K., Heine M., and Tassinari L. Effects of chronic excess salt ingestion. Further demonstration that genetic factors influence that development of hypertension: Evidence from experimental hypertension due to cortisone and to adrenal regeneration. J. Exp. Med. 122 (1965) 533-545
77. Dahl L.K., Knunsen K.D., Heine M., and Leitl G. Effects of chronic salt ingestion. Genetic influence of the development of salt hypertension in parabiotic rats: Evidence for humoral factor. J. Exp. Med. 126 (1967) 687-699
78. Dahl L.K., Heine M., and Thompson K. Genetic influence of renal homografts on blood pressure of rats from different strains. Proc. Soc. Exp. Biol. Med. 140 (1972) 852-856
79. Dahl L.K., Heine M., and Thompson K. Genetic influence of the kidneys on blood pressure. Evidence from chronic renal homografts in rats with opposite predispositions to hypertension. Circ. Res. 34 (1974) 94-101
80. Dahl L.K., and Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ. Res. 36 (1975) 692-696
81. Damas J., and Adams A. Congenital deficiency in plasma kallikrein and kininogens in the Brown Norway rat. Experientia 36 (1980) 586-587
82. de Champlain J., Petrovich M., Gonzalez M., Lebeau R., and Nadeau R. Abnormal cardiovascular reactivity in borderline and mild essential hypertension. Hypertension 17 Suppl. 5 (1991) III-2-III-28
83. Dilley J.R., Stier C.T.J., and Ardendshorst W.J. Abnormalities in glomerular function in rats developing spontaneous hypertension. Am. J. Physiol. 246 (1984) F12-F20
84. Donaldson V.H., Glueck H.I., Millar M.A., Movat H.Z., and Habal F. Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis. J. Lab. Clin. Med. 87 (1976) 327-337
85. Dussaule J.-C., Grange J.-D., Wolf J.-P., Lecomte J.-M., Gros C., Schwartz J.-C., Bodin F., and Ardaillou R. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J. Clin. Endocrinol. Metab. 72 (1991) 653-659
86. Dzau V.J., Pratt R., and Gibbons G.H. Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. Drugs 47 Suppl.4 (1994) 1-3
87. Eagan B.M. Neurogenic mechanisms of initiating essential hypertension. Am. J. Hypertens. 2 (1989) 357S-362S
88. Edwards O.M., Adetuyibi A., and Mills I.H. Kallikrein excretion during the "escape" from the sodium retaining effect of fludrocortisone. J. Endocrinol. 59 (1973) xxxiv
89. El-Dahr S.S., and Chao J. Spatial and temporal expression of kallikrein and its mRNA during nephron maturation. Am. J. Physiol. 262 (1992) F705-F711
90. Elliot A.H., and Nuzum F.R. The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18 (1934) 462
91. Erdös E.G., and Skidgel R.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormone. FASEB J. 3 (1989) 145-151
92. Erdös E.G. Some old and some new ideas on kinin metabolism. J. Cardiovasc. Pharmacol. 15 Suppl. 6 (1990) 520-524
93. Falkenhahn M., Gohlke P., Stoll M., and Unger T. The renin-angiotensin system in the heart and vascular wall: New therapeutic aspects. J. Cardiovasc. Pharmacol. 24 Suppl. 2 (1994) S6-S13
94. Falloon B.J., Bund S.J., Tulip J.R., and Heagerty A.M. In vitro perfusion studies of resistance artery function in genetic hypertension. Hypertension 22 (1993) 486-495
95. Favre L., Jornot L., Riodel A., and Vallotton M. Urinary excretion of renal prostaglandins, kallikrein, vasopressin and aldosterone in essential hypertension. Clin. Exp. Hypertens. 7 (1985) 1663-1679
96. Fejes-Toth G., Zahajszky T., and Filep J. Effect of vasopressin on renal kallikrein excretion. Am. J. Physiol. 239 (1980) F388-F392
97. Fejes-Toth G., Zahajszky T., and Filep J. Effect of vasopressin on the renal kallikrein-kinin system. Agents Actions 9 Suppl. (1982) 491-495
98. Fenoy F.J., Scicli G., Carretero O.A., and Roman R.J. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991 (1988) 1038-1044
99. - -cotransporter mediated RB+ fluxes in membrane vesicles from kidneys of normotensive and hypertensive rats. Biochim. Biophys. Acta 1021 (1990) 13-20
100. Ferrari P., Ferrandi M., Torielli L., Canessa M., and Bianchi G. Relationship between erythrocyte volume and sodium transport in the Milan hypertensive rat and age-dependent changes. J. Hypertens. 5 (1987) 199-206
101. Ferrari P., Torielli L., Cirillo M., Salardi S., and Bianchi G. Sodium transport kinetics in erythrocytes and inside-out vesicles from Milan rats. J. Hypertens. 9 (1991) 703-711
102. - cotransport in resealed ghosts from erythrocytes of the Milan hypertensive rats. Biochim. Biophys. Acta 1111 (1992) 111-119
103. Ferri C., Bellini C., Carlomagno A., Perrone A., and Santucci A. Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int. 46 (1994) 708-788
104. Figueroa C.D., Aorst I., and Vio C.P. Visualization of renal kallikrein in luminal and basolateral membranes: Effect of tissue processing method. J. Histochem. Cytochem. 32 (1984) 1238-1240
105. Figueroa C.D., Caorsi I., Subiabre J., and Vio C.P. Immunoreactive kallikrein localization in the rat kidney: An immuno-electron-microscopic study. J. Histochem. Cytochem. 32 (1984) 117-121
106. Figueroa C.D., Maclver A.G., Mackenzie J.C., and Bhoola K.D. Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 89 (1988) 437-442
107. Figueroa C.D., Maclver A.G., and Bhoola K.D. Identification of immunoreactive tissue kallikrein in human polymorphonuclear leucocytes. Br. J. Haematol. 72 (1989) 321-328
108. Figueroa C.D., Bhoola K.D., Maciver A.G., and Mackenzie J.C. An ontogenic study of renal tissue kallikrein in Okamoto spontaneously hypertensive rats: Comparison with human hypertensive nephropathy. Nephrol. Dial. Transplant. 7 (1992) 516-525
109. Figueroa C.D., Henderson L.M., Kaufman J., De la Cadena R.A., Colman R.W., Mueller-Esterl W., and Bhoola K.D. Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated neutrophils. Blood 79 (1992) 754-759
110. Figueroa C.D., Gonzalez C.B., Grigoriev S., Alia S.A., Haasemann M., Jarnagin K., and Mueller-Esterl W. Probing for the bradykinin B2 receptor in rat kidney by antipeptide and anti-ligand antibodies. J. Histochem. Cytochem. 43 (1995) 137-148
111. Fitzgibbon W.R., Jaffa A.A., Mayffield R.K., and Ploth D.W. Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Hypertension 27 (1996) 235-244
112. Frey E.K., and Kraut H. Ein neues Kreislaufhormonen und seine Wirkung. Arch. Exp. Pathol. Pharmacol. 133 (1928) 1-56
113. Fuller P.J., Clements A.J., Nikolaidis I., Hiwatari M., and Funder J.W. Expression of the renal kallikrein gene in mineral corticoid-treated and genetically hypertensive rats. J. Hypertens. 4 (1986) 427-433
114. Garay R.P., Nazaret P., and Price M. Abnormal Na+, K+ cotransport function in a group of patients with essential hypertension. Eur. J. Clin. Invest. 13 (1983) 311-320
115. 2 interrelationships. J. Clin. Invest. 74 (1984) 63-74
116. Geiger R., and Mann K. A kallikrein-specific inhibitor in rat kidney tubules. Hoppe Seylers Z. Physiol. Chem. 375 (1976) 523-528
117. Geiger R., Clausnitzer B., Fink E., and Fritz H. Isolation of an enzymatically active glandular kallikrein from human plasma. Hoppe Seylers Z. Physiol. Chem. 1361 (1980) 1795-1803
118. Geller R.G., Margolius H.S., Pisano J.J., and Keiser H.R. Effects of mineralcorticoids, altered sodium intake and adrenalectomy on urinary kallikrein in rats. Circ. Res. 31 (1972) 857-861
119. Geller R.G., Margolius H.S., Pisano J.J., and Keiser H.R. Urinary kallikrein excretion in spontaneously hypertensive rats. Circ. Res. 36 Suppl. I (1975) 1-103 1-106
120. Gelpi R.J., Hittinger L., Fujii A.M., Crocker V.M., Mirsky I., and Vatner S.F. Sympathetic augmentation of cardiac function early in developing hypertension in conscious dogs. Am. J. Physiol. 255 (1988) H1525-H1534
121. Gilboa N., Rudofsky U., and Magro A. Urinary and renal kallikrein in hypertensive fawn-hooded (FH/Wjd) rats. Lab. Invest. 50 (1984) 72-78
122. Gill J.R.J., Melmon K.L., Gillepsie L.J., and Bartter F.C. Bradykinin and renal function in normal man: Effects of adrenergic blockade. Am. J.Physiol. 209 (1965) 844-848
123. Girolami J.P., Praddasude F., Ader J.L., Tranvan T., Eche J.P., and Sue S.P. Bilateral urinary kallikrein excretion in the Goldblatt hypertensive rats. Eur. Heart J. 4 (1983) 67-72
124. Goldberg L.I., Dollery C.T., and Pentecost B.L. Effects of intrarenal infusions of bradykinin and acetylcholine on renal blood flow in man. J. Clin. Invest. 44 (1965) 1052
125. Greco A.V., Procelli G., Croxatto H.R., Fedeli G., and Ghirlanda G. Ipertensione arteriosa e callicreina urinarria. Minerva Med. 65 (1974) 3058-3062
126. Grenfell S.J., Albano J.D., and Waller D.G. Kallikrein release from the kidney: In vitro effects of AVP and DDAVP in three species. Arch. Int. Pharmacodyn. Ther. 292 (1988) 281-285
127. Gros C., Souque A., Schwartz J.-C., Duchier J., Cournot A., Baumer P., and Lecomte J.-M. Protection of atrial natriuretic factor against degradation: Diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetophan. Proc. Natl. Acad. Sci. USA 86 (1989) 7580-7584
128. Hagiwara Y., Kojima M., Hayashi I., and Oh-ishi S. Demonstration of derivation of rat urinary bradykinin from plasma low-molecular-weight kininogen: A study using kininogen-deficient rats. Biochem. Biophys. Res. Commun. 204 (1994) 1219-1224
129. Hajj-ali A.F., and Zimmerman B.G. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 17 (1991) 504-509
130. Hajj-ali A.F., and Zimmerman B.G. Enhanced blood pressure and renal hemodynamic effect of chronic verses acute lininopril administration in the rabbit. J. Pharmacol. Exp. Ther. 263 (1992) 158-162
131. Halushka P.V., Wohltmann H., Privitera P.J., Hurwitz G., and Margolius H.S. Bartter's syndrome: Urinary prostaglandin E-like material and kallikrein; indomethacin effects. Am. Intern. Med. 87 (1977) 281-286
132. Hasstedt S.T., Hunt S.C., Wu L.L., and Williams R.R. The inheritance of intraerythrocytic sodium level. Am. J. Med. Genet. 29 (1988) 193-203
133. Hasstedt S.T., Hunt S.C., Wu L.L., and Williams R.R. Hypertension and sodium-lithium countertransport in Utah pedigrees: Evidence for major locus inheritance. Am. J. Hum. Genet. 43 (1988) 14-22
134. Hatake K. Behavior of the kallikrein-kinin system on alcohol ingestion. Jpn. J. Alcohol Drug Depend. 19 (1984) 32-62
135. Hatanaka K., and Katori M. Mechanism of the passage of polymorphonuclear leukocytes between endothelial cells in hamster cheek pouch. Microcirc. Annu. 9 (1993) 153-154
136. Hayashi H., Koya H., Kitajima K., and Kitamura I. Coagulation factor deficiency apparently related to the Fitzgerald trait: The first case in Japan. Acta Med. Okayama 32 (1978) 81-83
137. Hayashi I., Hoshiko S., Manabe O., and Oh-ishi S. A point mutation of Alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of Brown Norway Katholiek rats. J. Biol. Chem. 268 (1993) 17219-17224
138. Haynes R.C., and Murad F. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs: Inhibition of adrenocortical steroid biosynthesis. The Pharmacological Basis of Therapeutics (1985), MacMillan, New York. 1459-1489
139. Heller J., Kramer H.J., and Horacek V. The effect of kinin and prostaglandin inhibitors on the renal response to angiotensin-converting enzyme inhibition: A micropuncture study in the dog. Pflugers Arch. 427 (1994) 219-224
140. Henderson L.M., Figueroa C.D., Mueller-Esterl W., and Bhoola K.D. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 84 (1994) 474-482
141. Hial V., Keiser H.R., and Pisano J.J. Origin and content of methionyl-lysyl-bradykinin, lysyl-bradykinin and bradykinin in human urine. Biochem. Pharmacol. 25 (1976) 2499-2503
142. Hilme E., Herlitz H., Gyzander E., and Hansson L. Urinary kallikrein excretion is low in malignant essential hypertension. J. Hypertens. 10 (1992) 869-874
143. Himathongkam T., Dulhy R.G., and Williams G.H. Potassium-aldosterone-renin interrelationships. J. Clin. Endocrinol. Metab. 41 (1975) 153-159
144. Hirata Y., Matsuoka H., Hayakawa H., Sugimoto T., Suzuki E., Sugimoto T., Kanagawa K., and Matsuo H. Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rats. Hypertension 17 (1991) 1025-1032
145. Holland B., Chud J.M., and Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J. Clin. Invest. 65 (1980) 347-356
146. Horwitz D., Margolius H.S., and Keiser H.R. Effects of potassium intake on urinary kallikrein. Clin. Res. 23 (1975) 221A
147. Horwitz D., Margolius H.S., and Keiser H.R. Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J. Clin. Endocrinol. Metab. 47 (1978) 296-299
148. Hunt S.C., Hasstedt S.J., Wu L.L., and Williams R.R. A gene-environmental interaction between inferred kallikrein genotype and potassium. Hypertension 22 (1993) 161-168
149. Hunt S.C., Slattery M.A., Meikle A.W., and Williams R.R. Environmental determinants of urinary kallikrein excretion. Am. J. Hypertens. 6 (1993) 226-233
150. Ideishi M., Miura S., Sakai T., Misumi Y., and Arakawa K. Taurine amplifies renal kallikrein and prevents salt-induced hypertension in Dahl rats. J. Hypertens. 12 (1994) 653-661
151. Ikemoto F., Song G.B., Tominaga M., Kanayama Y., and Yamamoto K. Angiotensin-converting enzyme in the rat kidney. Activity, distribution, and response to angiotensin-converting enzyme inhibitors. Nephron 55 Suppl. (1990) 3-9
152. Inoue H., Fuki K., and Miyake Y. Identification and structure of the rat true tissue kallikrein gene expressed in the kidney. J. Biochem. 105 (1989) 834-840
153. Ishida H., Scicli A.G., and Carretero O.A. Contributions of various rat plasma peptidases to kinin hydrolysis. J. Pharmacol. Exp. Ther. 251 (1989) 817-820
154. Ito H., Majima M., Izumi T., and Katori M. Complete inhibition of development of DOCA-salt hypertension by prolonged administration of an urinary carboxypeptidase Y-like kininase inhibitor ebelactone B. Hypertension 30 (1997) P83 (abstract).
155. Iwai J., Knudsen K.D., Dahl L.D., Heine M., and Leitl G. Genetic influence on the development of renal hypertension in parabiotic rats. J. Exp. Med. 129 (1969) 507-522
156. Iwai N., Matsunaga M., Kita T., Tei M., and Kawai Ch. Detection of low molecular kininogen messenger RNA in human kidney. J. Hypertens. 6 Suppl. 4 (1988) S399-S400
157. Jardine A.G., Connell J.M.C., Northridge D., Dilly S.G., Cussans N.J., Davidson G., Doyle J., Leckie B.L., and Lever A.F. The atriopeptidase inhibitor UK 69, 578 increases atrial natriuretic factor and caused natriuresis in normal humans. Am. J. Hypertens. 3 (1990) 661-667
158. Jeunemaitre X., Lifton R.P., Hunt S.C., Williams R.R., and Lalouel J.-M. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat. Genet. 1 (1992) 72-75
159. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., Lifton R.P., Williams C.S., Charru A., Hunt S.C., Hopkins P.N., Williams R.R., Lalouel J.-M., and Corvol P. Molecular basis of human hypertension: Role of angiotensinogen. Cell 71 (1992) 169-180
160. Johnston C.I., Matthews P.G., and Dax E. Effects of dietary sodium, diuretics, and hypertension on renin and kallikrein. Systemic Effects of Antihypertensive Agents (1976), Stratton Intercontinental, New York. 323-338
161. Kaizu T., and Margolius H.S. Studies on rat renal cortical cell kallikrein. 1. Separation and measurement. Biochim. Biophys. Acta 411 (1975) 305-315
162. Kaplan A.P., Silverberg M., and Ghebrehiwet B. The intrinsic coagulationJkinin pathway-The classical complement pathway and their interactions. Kinins IV, Part B (1986), Plenum Press, New York. 11-25
163. Kato H., Enjyoji K., Miyata T., Hayashi I., Oh-ishi S., and Iwanaga S. Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: Direct evidence for liberation of bradykinin by rat glandular kallikreins. Biochem. Biophys. Res. Commun. 127 (1985) 289-295
164. 4 in inflammatory models. Dermatologia 179 Suppl. (1989) 60-63
165. Katori M., Majima M., Odoi-Adome R., Sunahara N., and Uchida Y. Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br. J. Pharmacol. 98 (1989) 1383-1391
166. Katori M., Majima M., Mohsin S.S.J., Hanazuka M., and Mizokami S. Essential role of kallikrein-kinin system in suppression of blood pressure rise during the developmental stage of hypertension induced by deoxycorticosterone acetate-salt in rats. Agents Actions 38 Suppl. (1992) 235-242
167. Katori M., and Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn. J. Pharmacol. 70 (1996) 95-128
168. 22 Na in the rat nephron. J. Pharmacol. Exp. Ther. 214 (1980) 119-123
169. Kauker M.L., Crofton J.T., Share L., and Nasjletti A. Role of vasopressin in regulation of renal kinin excretion in Long-Evans and diabetes inspidus rats. J. Clin. Invest. 72 (1984) 824-831
170. Kawabe K., Watanabe T., Shiono K., and Sokabe H. Influence on blood pressure of renal isografts between spontaneously hypertensive and normotensive rats using Fl hybrids. Jpn. Heart J. 19 (1978) 886-894
171. Keiser H.R., Andrews M.J.J., Guyton R.A., Margolius H.S., and Pisano J.J. Urinary kallikrein in dogs with constriction of one renal artery. Proc. Soc. Exp. Biol. Med. 151 (1976) 53-56
172. Keiser H.G., Geller R.G., Margolius H.S., and Pisano J.J. Urinary kallikrein in hypertensive animal models. Fed. Proc. 35 (1976) 199-202
173. Keiser H.R. The kallikrein-kinin system in essential hypertension. Clin. Exp. Hypertens. 2 (1979) 675-691
174. Kenny A.J., and Stephenson S.L. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 232 (1980) 1-8
175. Knundsen K.D., Iwai J., Heine M., Leitl G., and Dahl L.K. Genetic influence on the development of renoprivial hypertension in parabiotic rats. J. Exp. Med. 130 (1969) 1353-1365
176. Komers R., and Cooper M.E. Acute renal hemodynamic effect of ACE inhibition in diabetic hyperfiitration: Role of kinins. Am. J. Physiol. 268 (1995) F588-F594
177. Kon V., Fogo A., and Ichikawa I. Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int. 66 (1993) 545-550
178. Koolen M.L., Daha M.R., Frolich M., Van Es L.A., and Van Brummelen P. Direct and indirect measurement of urinary kallikrein excretion in patients with essential hypertension and normotensives: Relation to age and plasma renin and aldosterone levels. Eur. J. Clin. Invest. 14 (1984) 171-174
179. Kosoglou T., Herron J.M., Chen R., Given B., Sybertz E.J., and Affrime M.B. Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension. Circulation 82 Suppl. II (1990) 2201
180. Kuribayashi Y., Majima M., and Katori M. Major kininases in rat urine are neutral endopeptidase and carboxypeptidase Y-like exopeptidase. Biomed. Res. 14 (1993) 191-201
181. Kurtz T.W., Simonet K., Kabra P.M., Wolfe S., Chan L., and Hjelle B.L. Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J. Clin. Invest. 85 (1990) 1328-1332
182. Lacombe M.J., Varet B., and Levey J.-P. A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): Case report and coagulation studies. Blood 46 (1975) 761-768
183. Lattion A.-L., Baussant T., Alhenc-Gelas F., Seidah N.G., Corvol P., and Soubrier F. The high-molecular-mass kininogen deficient rat expresses all kininogen mRNA species, but does not export the high-molecular-mass kininogen synthetized. FEBS Lett. 239 (1988) 59-64
184. Lawton W.J., and Fitz A.E. Urinary kallikrein in normal renin essential hypertension. Circulation 56 (1977) 856-859
185. Lawton W.T., Proud D., French M.E., Pierce J.V., Reiser H.R., and Pisano J.J. Characterization and origin of immunoreactive glandular kallikrein in rat plasma. Biochem. Pharmacol. 30 (1981) 11731-11737
186. Leake R.D., Weitzman R.E., Glatz T.H., and Fisher D.A. Plasma oxytocin concentrations in men, nonpregnant women, and pregnant women before and during spontaneous labor. J. Clin. Endocrinol. Metab. 53 (1981) 730-733
187. Lechi A., Covi G., Lechi C., Mantero F., and Scuro L.A. Urinary kallikrein excretion in Bartter's syndrome. J. Clin. Endocrinol. Metab. 43 (1976) 1175-1178
188. Lechi A., Covi G., Lechi C., Corquati A., Arosio E., Zatti M., and Scuro L.A. Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism. Clin. Sci. Mol. Med. 55 (1978) 51-55
189. Lecomte J.-M., Baumer P., Lim C., Duchier J., Cournot A., Dussaule J.-C., Araillou R., Gros C., Chaignon B., Souque A., and Schwartz J.-C. Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Ear. J. Pharmacol. 179 (1990) 65-73
190. Levinskey N.G. The renal kallikrein-kinin system. Circ. Res. 44 (1979) 441-451
191. Levy S.B., Lilly J.J., Frigon R.P., and Stone L.A. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. J. Clin. Invest. 60 (1977) 129-138
192. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting enzyme inhibition on diabetic nephropasy. N. Engl. J. Med. 329 (1993) 1456-1462
193. Lieberthal W., Oza N.B., Bernard D.B., and Levinsky N.G. Effects of alterations in sodium and water metabolism on urinary excretion of active and inactive kallikrein in man. J. Clin. Endocrinol. Metab. 56 (1983) 513-519
194. + antiporter as a candidate gene in human essential hypertension. Hypertension 17 (1991) 8-14
195. Lindpaintner K., Niedermaier N., Drexler H., and Ganten D. Left ventricular remodelling after myocardial infarction: Does the cardiac renin-angiotensin system play a role?. J. Cardiovasc. Pharmacol. 20 Suppl. 1 (1992) S41-S47
196. Linz W., Wiemer G., and Schoelkens B.A. Contribution of bradykinin to the cardiovascular effects of ramipril. J. Cardiovasc. Pharmacol. 22 Suppl. (1993) S1-S8
197. 2 receptor. Genomics 23 (1994) 362-369
198. Ma J.-X.A., Yang Z., Chao J., and Chao L. Intramuscular delivery of rat kallikrein-binding protein gene reversed hypotension in transgenic mice expressing human tissue kallikrein. J. Biol. Chem. 270 (1995) 451-455
199. Madeddu P., Anania V., Parpaglia P.P., Demontis M.P., Varoni M.V., Fattaccio M.C., and Glorioso N. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br. J. Pharmacol. 108 (1993) 651-657
200. Madeddu P., Parpaglia P.P., Demontis M.P., Varoni M.V., Fattaccio M.C., Tonolo G., Troffa C., and Glorioso N. Bradykinin B2-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension 21 (1993) 980-984 (6, Pt.2)
201. Madeddu P., Parpaglia P.P., Demonis M.P., Varoni M.V., Fattacio M.C., Anania V., and Glorioso N. Effects of kinin blockade on the blood pressure of salt-loaded pregnant rats. II. Hypertension 25 (1995) 823-827
202. Madeddu P., Parpaglia P.P., Demontis M.P., Varoni M.V., Fattaccio M.C., Anania V., and Glorioso N. Early blockade of bradykinin B2-receptor alters the adult cardiovascular phenotype in rats. Hypertension 25 (1995) 453-459
203. Maeda H., and Yamamoto T. Pathogenic mechanisms induced by microbial proteases in microbial infection. Biol. Chem. Hoppe-Seyler 377 (1996) 217-226
204. Maier M., and Binder B.B. Dependence of urokallikrein excretion on the perfusion pressure in explanted perfused kidneys. Kinin-II, Biochemistry, Pathophysiology, and Clinical Aspects (1978), Plenum Press, New York. 527-538
205. Majima M., Tani Y., and Katori M. Loss of the activity of human coagulation factor XII by a chymotrypsin-like protease activated in rat mast cells during degranulation by compound 48/80. Thromb. Res. 46 (1987) 855-867
206. Majima M., Katori M., Hanazuka M., Mizogami S., Nakano T., Nakao Y., Mikami R., Uryu H., Okamura R., Mohsin S.S.J., and Oh-ishi S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 17 (1991) 806-813
207. Majima M., Shima C., Saito M., Kuribayashi Y., Katori M., and Aoyagi T. Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine. Eur. J. Pharmacol. 232 (1993) 181-190
208. Majima M., Sunahara N., Harada Y., and Katori M. Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem. Pharmacol. 45 (1993) 559-567
209. Majima M., Yoshida O., Mihara H., Muto T., Mizogami S., Kuribayashi Y., Katori M., and Oh-sihi S. High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 22 (1993) 705-714
210. Majima M., Kuribayashi Y., Ikeda Y., Adachi K., Kato H., Katori M., and Aoyagi T. Diuretic and natriuretic effect of ebelactone B in anesthetized rats by inhibition of a urinary carboxypeptidase Y-like kininase. Jpn. J. Pharmacol. 65 (1994) 79-82
211. Majima M., Kuribayashi Y., and Katori M. A novel type of antihypertensive drugs, poststatin and ebelactone B, acting through urinary kininase inhibition. Can. J. Pharmacol. Physiol. 72 Suppl. I (1994) 129
212. Majima M., Mizogami S., Kuribayashi Y., Katori M., and Oh-ishi S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24 (1994) 111-119
213. Majima M., Adachi K., Kuribayashi Y., Mizogami S., and Katori M. Increase in vascular sensitivity to angiotensin II and norepinephrine after four-day infusion of 0.3 M sodium chloride in conscious kininogen-deficient Brown Norway Katholiek rats. Jpn. J. Pharmacol. 69 (1995) 149-158
214. Majima M., Ikeda Y., Kuribayashi Y., Mizogami S., Katori M., and Aoyagi T. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats. Eur. J. Pharmacol. 284 (1995) 1-11
215. Majima M., and Katori M. Approaches to the development of novel antihypertensive drugs: Crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci. 16 (1995) 239-246
216. Majima M., Adachi K., Ohno T., Ogino M., Saito M., Kizuki K., Katsunuma O., Yama-shina S., and Katori M. Failure of the oxytocin-induced increase in secretion of urinary kallikrein in young spontaneously hypertensive rats. Jpn. J. Pharmacol. 71 (1996) 11-19
217. Majima M., Katori M., Ogino M., Saito M., Sugimoto K., Adachi K., Ohno T., Sunahara N., Katoh K., Tatemichi N., and Takei Y. Failure of endogenous blood kinin levels elevated by captopril to induce hypotension in normotensive and hypertensive rats: A study using a newly developed ELISA for kinin. Biochem. Res. 17 (1996) 15-25
218. Majima M., Nishiyama K., Yao K., Ogino M., Ohno T., Sunahara N., Katoh K., Takema-chi N., Takei Y., and Katori M. Determination of bradykinin-(l-5) in the inflammatory exudate by a new ELISA as a reliable mediator for bradykinin generation. Inflamm. Res. 45 (1996) 416-423
219. Marchetti J., Imbert-Teboul M., Alhec-Gelas F., Allegrini J., Menard J., and Morel F. Kallikrein along the rabbit microdissected nephron: A micromethod for its measurement. Effect of adrenalectomy and DOCA treatment. Pflugers Arch. 401 (1984) 27-33
220. Marchetti J., Roseau S., and Alhenc-Gelas F. Angiotensin I converting enzyme and kinin-hydrolyzing enzymes along the rabbit single nephron. Kidney Int. 31 (1987) 744-751
221. Margolius H.S., Geller R., Pisano J.J., and Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet ii (1971) 1063-1065
222. Margolius H.S., Horwitz D., Geller R.G., Alexander R.W., Gill Jr. J.R., Pisano J.J., and Keiser H.R. Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35 (1974) 812-819
223. Margolius H.S., Horwitz D., Pisano J.J., and Keiser H.R. Urinary kallikrein excretion in hypertensive man: Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35 (1974) 820-825
224. Margolius H.S. Tissue kallikreins and kinins: Regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 343-364
225. Margolius H.S. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26 (1995) 221-229
226. Marin-Grez M., and Carretero O.A. Urinary kallikrein excretion in rats under low and high sodium intake. Physiologist 14 (1971) 189
227. Marin-Grez M. The influence of antibodies against bradykinin on isotonic saline diuresis in the rat. Evidence for kinin involvement in renal function. Pflugers Arch. 350 (1974) 231
228. Marin-Grez M., Boenner G., and Gross F. The influence of isotonic saline administration of the urinary excretion of kallikrein in rats. Biochem. Pharmacol. 33 (1984) 3585-3590
229. Marinkovi D.V., Ward P.E., Erdoes E.G., and Mills I.H. Carboxypeptidase-type kininase of human kidney and urine. Proc. Soc. Exp. Biol. Med. 156 (1980) 6-12
230. Marshall K.G., Waller D.G., and Albono J.D.M. Kallikrein and kinin release using superfused disaggregated cortical cells from rat and human kidney: Effects of AVP and dopamine. Agents Actions 38 (1992) 134-141
231. Mattson D.L., and Roman R.J. Role of kinins and angiotensin in the renal hemodynamic response to captopril. Am. J. Physiol. 260 (1991) F670-F679
232. Mayfield R.K., and Margolius H.S. Renal kallikrein-kinin system. Relation to renal function and blood pressure. Am. J. Nephrol. 3 (1983) 145-155
233. McCaa C.S., and McCaa R.E. Response of the kallikrein-kinin system to continuous infusion of angiotensin I converting enzyme inhibitor (SQ 20881) into intact conscious dog. Clin. Res. 25 (1977) 61A
234. McEachern A.E., Shelton E.R., Bhakta S., Obernolte R., Bach C., Suppan P., Fujisaki J., Aldrich R.W., and Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc. Natl. Acad. Sci. USA 88 (1991) 7724-7728
235. McGiff J.C., Itskovitz H.D., and Tarragno N.A. The actions of bradykinin and eledoisin in the canine isolated kidney: Relation to prostaglandins. Clin. Sci. Mol. Med. 49 (1975) 125-131
236. McNay J.L., and Goldberg G.H. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J. Pharmacol. Exp. Ther. 151 (1966) 23-31
237. McPartland R.P., Rapp J.P., and Sustarsic D.L. Effects of dexamethasone on excretion of urinary kallikrein and urinary protein in Dahl salt-sensitive and salt-resistant rats. Endocr. Res. Commun. 8 (1981) 145-153
238. Mersey J.H., Williams G.H., Emanuel R., Dluhy R.G., Wong P.Y., and Moore T.J. Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension. J. Clin. Endocrinol. Metab. 48 (1979) 642-647
239. Mills I.H. Renal kallikrein and regulation of blood pressure in man Bradykinin, Kallidin and Kallikrein. Handbook of Experimental Pharmacology 25 (1975), Springer-Verlag, New York. 549-567
240. Mills I.H., and Ward P.E. The relationship between kallikrein and water excretion and the conditional relationship between kallikrein and sodium excretion. J. Physiol. 246 (1975) 695-707
241. Mimura T., Hayashi I., Hoshino T., and Oh-ishi S. Demonstration of high-molecular-weight kininogen in kininogen-deficient rat kidneys. J. Biochem. 116 (1994) 59-63
242. Misumi J., Alhenc-Gelas F., Marre M., Marchetti J., Corvol P., and Menard J. Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney Int. 24 (1983) 58-65
243. Mitas J.A., Levy S.B., Holle R., Frigon R.P., and Stone R.A. Urinary kallikrein activity in the hypertension of renal parenchymal disease. N. Engl. J. Med. 299 (1978) 162-165
244. Miyashita A. Urinary kallikrein determination and its physiological role in human kidney. J. Urol. 62 (1971) 507-518
245. Mohsin S.S.J., Majima M., Katori M., and Sharma J.N. Important suppressive roles of the kallikrein-kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pac. J. Pharmacol. 7 (1992) 73-82
246. Mosconi L., Ruggenent P., Perna A., Mecca G., and Remuzzi G. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney-Int. 55 (1996) S91-S93
247. Naftilan A.J., Williams R.R., Burt D., Paul M., Pratt R.E., Hobart P., Chirgwin J., and Dzau V.J. A lack of genetic linkage of renin gene restriction fragment length polymorphism with human hypertension 4 (1989) 614-618
248. Nakahashi Y., Shimamoto K., Ura N., Tanaka S., Nishitani T., Ishida H., Yokoyama T., Ando T., and Iimura O. Comprehensive studies on the renal kallikrein-kinin system in essential hypertension. Kinins III, Part B (1983), Plenum Press, New York. 351-357
249. Nakamura K., Iijima K., Fukuda C., Kadowaki H., Ikoma H., Oh-ishi S., Uchida Y., and Katori M. Tachibana trait: Human high molecular weight kininogen deficiency with diminished levels of prekallikrein and low molecular weight kininogen. Acta Hematol. Jpn. 48 (1983) 1473-1479
250. Nakano J. Effects of synthetic bradykinin on the cardiovascular system. Arch. Intern. Pharmacodyn. 157 (1965) 1-13
251. Nasjletti A., Colina-Chourio J., and McGiff J.C. Disappearance of bradykinin in the renal circulation of dogs. Circ. Res. 37 (1975) 59
252. Nasjletti A., and Colina-Choourio J. Interaction of mineralocorticoids, renal prostaglandins, and the renal kallikrein-kinin system. Fed. Proc. 35 (1976) 59-65
253. Nishimura K., Alhenc-Gelas F., White A., and Erdos E.G. Activation of membrane bound kallikrein and renin in the kidney. Proc. Natl. Acad. Sci. USA 77 (1980) 4975-4978
254. Northridge D.B., Jardine A.G., Findlay I.N., Archibald M., Dilly S.G., and Dargie H.J. Inhibition of the metabolism of atrial natriuretic factor caused diuresis and natriuresis in chronic heart failure. Am. J. Hypertens. 3 (1990) 682-687
255. Nossel H.L. The contact system. Human Blood Coagulation, Haemostasis and Thrombosis (1972), Blackwell Science, London. 79-132
256. Nustad K., Orstravik T.B., and Gautivik K.M. Radioimmunological measurement of rat submandibular gland kallikrein in tissue and serum. Microvasc. Res. 15 (1978) 115-116 (abstract).
257. Ogata H., Ura N., Shimamoto K., Sakakibara T., Ando T., Nishimiya T., Nakagawa M., Fukuyama S., Masuda A., Yamaguchi Y., Ise T., Saito S., Shiki M., Uno K., and Iimura O. A sensitive method for differential determination of kininase I, II and neutral endopeptidase (NEP) in human urine. Kinins V (1989), Plenum Press, New York. 343-348
258. Ogihara T., Rakugi H., Masuo K., Yu H., Nagano M., and Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am. J. Hypertens. 7 (1994) 943-947
259. Oh-ishi S., Ueno A., Uchida Y., Katori M., Hayashi H., Koya H., Kitajima K., and Kimura I. Abnormalities in the contact activation through factor XII in Fujiwara trait: A deficiency in both high and low molecular weight kininogens with low level of prekallikrein. Tohoku J. Exp. Med. 133 (1981) 67-80
260. Oh-ishi S., Satoh K., Hayashi I., Yamazaki K., and Nakano T. Differences in prekallikrein and high molecular weight kininogen levels in two strains of Brown Norway rat (Kitasato strain and Katholiek strain). Thromb. Res. 28 (1982) 143-147
261. Oh-ishi S., Hayashi I., Satoh K., and Nakano T. Prolonged activated thromboplastin time and deficiency of high molecular weight kininogen in Brown Norway rat mutant (Katholiek strain). Thromb. Res. 33 (1984) 371-377
262. Oh-ishi S., Hayashi I., Hayashi M., Yamaki K., Yamasu A., Nakano T., Utsunomiya I., and Nagashima Y. Evidence for a role of the plasma kallikrein-kinin system in acute inflammation: Reduced exudation during carrageenin- and kaolin-pleurisies in kininogen-deficient rats. Agents Actions 18 (1986) 450-454
263. Oh-ishi S., Hayashi I., Utsunomiya I., Hayashi M., Yamaki K., Yamasu A., and Nakano T. Roles of kallikrein-kinin system in acute inflammation: Studies on high-and low-molecular weight kininogen-deficient rats (B/N-Katholiek strain). Agents Actions 21 (1987) 384-386
264. Oh-ishi S. Biological regulation by the kallikrein-kinin system: A study with a kininogen-deficient rat strain. Folia Pharmacol. Japonica 101 (1993) 209-218 (in Japanese)
265. Omata K., Carretero O.A., Scicli A.G., and Jackson B.A. Localization of active and inactive kallikrein in the isolated tubular segments of the rabbit nephron. Kidney Int. 22 (1982) 602-607
266. Omata K., Carretero O.A., Itoh S., and Scicli A.G. Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake. Kidney Int. 24 (1983) 714-718
267. Ostravik T.B., Nustad K., Brandtzaeg P., and Pierce J. Cellular origin of urinary kallikreins. J. Histochem. Cytochem. 24 (1976) 1037-1039
268. Ostravik T.B., and Inagami T. The localization of kallikrein in the rat kidney and its anatomical relationship to renin. J. Histochem. Cytochem. 30 (1982) 385-390
269. Parenti P., Hanozet G., and Bianchi G. Sodium and glucose transport across renal brush border membranes of Milan hypertensive rats. Hypertension 8 (1986) 932-939
270. Parenti P., Villa M., Hanozet G.M., Ferrandi M., and Ferrari P. Increased Napump activity in the kidney cortex of the Milan hypertensive rat strain. FEBS Lett. 290 (1991) 200-204
271. Pelacani A., Brunner H.R., and Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin. Sci. 87 (1994) 567-574
272. Pierce J.V., and Webster M.E. Human plasma kallikreins: Isolation and chemical studies. Biochem. Biophys. Res. Commun. 5 (1961) 353-357
273. Pisano J.J., Yates K., and Pierce J.V. Kininogen in human urine. Agents Actions 8 (1978) 1-2
274. Pisano J.J., and Marks E.S. The renal kallikrein-kinin system: A look at the controversiales. Kinin IV (1986), Plenum Press, New York. 193-205
275. Porcelli G., Bianchi G., and Croxatto H.R. Urinary kallikrein excretion in a spontaneously hypertensive strain of rats. Proc. Soc. Exp. Biol. Med. 149 (1975) 983-986
276. Praddaude F., Tran-Van T., and Ader J.L. Renal kallikrein activity in rats developing spontaneous hypertension. Clin. Sci. 76 (1989) 311-315
277. Pravenec M., Kren V., Kunes J., Scicli A.G., Carretero O.A., Simonet L., and Kurz T.W. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17 (1991) 242-246
278. Proud D., Perkins M., Pierce J.V., Yates K., Highet P., Herrig P., Mark M.M., Bahu R., Carone F., and Pisano J.J. Characterization and localization of human renal kininogen. J. Biol. Chem. 256 (1981) 10634-10639
279. Proud D., Knepper M.A., and Pisano J.J. Distribution of immunoreactive kallikrein along the rat nephron. Am. J. Physiol. 244 (1983) F510-F515
280. Quinn S.J., Cornwall M.C., and Williams G.H. Electric properties of isolated rat adrenal glomerulosa and fasciculata cells. Endocrinology 120 (1987) 903-914
281. Rabito S.F., Amin V., Scicli A.G., and Carretero O.A. Glandular kallikrein in plasma and urine. Kinins-II (1979), Plenum Press, New York. 127-142
282. Rapp J.P., Tan S.Y., and Margolius H.S. Plasma mineralcorticoids, plasma renin, and urinary kallikrein in salt-sensitive and salt-resistant rats. Endocr. Res. Commun. 5 (1978) 35-41
283. Rapp J.P., Joseph M.K., and McPartland R.P. Proteins binding to kallikrein and esterase A2 in the urine of salt-sensitive and salt-resistant rats. Hypertension 4 (1982) 545-555
284. Rapp J.P., McPartland R.P., and Sustarsic D.L. Anomalous response of urinary kallikrein to deoxycorticosterone in Dahl salt-sensitive rats. Hypertension 4 (1982) 20-26
285. Rapp J.P., McPartland R.P., and Batten C.L. Isoelectric focusing patterns of urinary kallikrein in Dahl salt-hypertension susceptible and resistant rats. Hypertension 6 (1984) 519-525
286. Rapp J.P., Wang S.-M., and Dene H. A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science 243 (1989) 542-544
287. Regoli D., and Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32 (1980) 1-46
288. Regoli D., Rhaleb N.-E., Drapeau G., and Dion S. Kinin receptor subtypes. J. Cardiovasc. Pharmacol. 15 Suppl. 6 (1990) s30-s38
289. Riegman P.H., Vlietstra R.J., Surmeijer L., Cleutjens C.B., and Trapman J. Characterization of the human kallikrein locus. Genomics 14 (1992) 6-11
290. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86 (1990) 1343-1346
291. Roberts R.A. Bradykinin receptors: Characterization, distribution and mechanisms of signal transduction. Prog. Growth Factor Res. 1 (1989) 237-252
292. Roman R.J., Kaldunski M.L., Scicli A.G., and Carretero O.A. Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am. J. Physiol. 255 (1988) F690-F698
293. Ronco P., Pollard H., Galceran M., Delauche M., Schwartz J.C., and Verroust P. Distribution of enkephalinase (membrane metalloendo-peptidase EC 3.4.24.11) in rat organs: Detection using a monoclonal antibody. Lab. Invest. 58 (1988) 210-217
294. Roques B.P., Fournie-Zaluski M.-C., Soroca E., Lecomte J.M., Malfroy B., Liorens C., and Schwarz J.-C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288 (1980) 286-288
295. Sagnella G.A., Singer D.R.J., Markandu N.D., Buckley M.G., and MacGregor G.A. Is atrial natriuretic peptide-guanosine 3', 5' cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension?. J. Hypertens. 10 (1992) 349-354
296. Saito M., Majima M., Katori M., Sanjou Y., Suyama I., Shiokawa H., Koshiba K., and Aoyagi T. Degradation of bradykinin inhuman urine by carboxypeptidase Y-like exopeptidases and their inhibition by ebelactone B and phosphoramidon. Int. J. Tissue React. 17 (1996) 181-190
297. Sakakibara T., Ura N., Shimamoto K., Mori Y., Saito S., Ise T., Sasa Y., Yamauchi K., and Iimura O. Localization of neutral endopeptidase in the kidney determined by the stop-flow method. Kinin V (1989), Plenum Press, New York. 349-353
298. Salardi S., Saccardo B., Borsani G., Modica R., Ferrandi M., Tripodi M.G., Soria M., Ferrari P., Baralle F.E., Sidoli A., and Bianchi G. Erythrocyte adducin differential properties in the normotensive and hypertensive rats of the Milan strain. Characterization of spleen adducin m-RNA. Am. J. Hypertens. 2 (1986) 229-237
299. Salvati P., Pinciroli G.P., and Bianchi G. Renal function of isolated perfused kidneys from hypertensive (MHS) and normotensive (MNS) rats of the Milan strain at different ages. J. Hypertens. 2 Suppl. 3 (1984) 351-353
300. Salvati P., Ferrario R.G., Parenti P., and Bianchi G. Renal function of isolated perfused kidneys from hypertensive (MHS) and normotensive (MNS) rats of the Milan strain: Role of calcium. J. Hypertens. 5 (1987) 31-38
301. Salvati P., Ferrario R.G., and Bianchi G. Diuretic effect of bumetanide in isolated perfused kidneys of Milan hypertensive rats. Kidney Int. 37 (1990) 1084-1089
302. Samani N.J., Brammar W.J., and Swales J.D. A major structural abnormality in the renin gene of the spontaneously hypertensive rat. J. Hypertens. 7 (1989) 249-254
303. Sasaki S., Takeda K., Okajima H., Takahashi H., Yoshimura M., Nakagawa M., and Ijichi H. Pressor responses to intracisternal injection of hypertonic NaCl in rats. J. Cardiovasc. Pharmacol. 6 (1984) 349-364
304. Sawyer W.H. Posterior pituitary extracts and excretion of electrolytes by the rat. Am. J. Physiol. 169 (1952) 493-583
305. Schölkens B.A. Kinins in the cardiovascular system. Immunopharmacology 33 (1996) 209-216 (special issue, Kinin '95 Part II)
306. Schulz W.W., Hagler H.K., Buja L.M., and Erdoes E.G. Ultrastructural localization of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubules of the human kidney. Lab. Invest. 59 (1988) 789-797
307. Scicli A.G., Mindroiu T., Scicli G., and Carretero O.A. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J. Lab. Clin. Med. 100 (1982) 81-93
308. Stephens G.W., Lieberthal W., Oza N.B., Valeri C.R., and Levinsky N.G. Vasopressin stimulates urinary kallikrein excretion in the isolated erythrocyte-perfused rat kidney. Renal Physiol. Biochem. 11 (1988) 50-59
309. Stephenson S.L., and Kenny A.J. The hydrolysis of a-human atrial natriuretic peptide by pig kidney microvillar membrane is initiated by endopeptidase-24.11. Biochem. J. 243 (1987) 183-187
310. Sudo J. Distribution of peptidases in the metabolization of peptide hormones, particularly angiotensin II, along the isolated single nephron of rat. Folia Pharmacol. Jpn. 78 (1981) 27-44 (in Japanese) (abstract in English).
311. Sugaya K., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., Goto S., Imaizumi K., Hisada Y., Otsuka A., Uchida H., Sugiura M., Fukuda K., Fukamizu S., and Murakami K. Angiotensin II type la receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270 (1995) 18719-18722
312. Sustarsic D.L., McPartland R.P., and Rapp J.P. Developmental patterns of blood pressure and urinary protein, kallikrein, and prostaglandin E2 in Dahl salt-hypertension-susceptible rats. J. Lab. Clin. Med. 98 (1981) 599-606
313. Suzuki E., Hirata Y., Matsuoka H., Sugimoto T., Hayakawa H., Sugimoto T., Kanagawa K., Minamino N., and Matsuo H. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor. Biochem. Biophys. Res. Comm. 182 (1992) 1270-1276
314. Sybertz E.J., Chiu P.J.S., Vemulapalli S., Pitts B., Foster C.J., Watkins R.W., Barnett A., and Haslanger M.F. SCH 39370, a neutral metalloendopeptidase inhibitor potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J. Pharmacol. Exp. Ther. 250 (1989) 624-631
315. Sybertz E.J., Chiu P.J.S., Vemulapalli S., Watkins R., and Haslanger M.F. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826-An orally active neutral metallopeptidase inhibitor. Hypertension 15 (1990) 152-161
316. Sybertz E.J. SCH 34826: An overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Clin. Nephrol. 36 (1991) 187-191
317. Sybertz E.J., Chiu P.J.S., Watkins R.W., and Vemulapalli S. Neutral metalloendopeptidase inhibitors as ANF potentiators: Sites and mechanisms of action. Can. J. Physiol. Pharmacol. 69 (1991) 1628-1635
318. Tanimoto K., Sugiyama F., Goto Y., Ishida J., Takimoto E., Yagami K., Fukamizu S., and Murakami K. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 269 (1994) 31334-31337
319. K. Tanimoto, S. Fukamizu, K. Murakami, F. Sugiyama, K. Yagami, (1995). Production of hypotensive mice deficient in angiotensinogen gene by a gene-targeting method. The 18th Annual Meeting of the Japanese Hypertension Society, Tokyo 1995.
320. Tikkanen I., Helin K., Tikkanen T., Sybertz E.J., Vemulapalli S., Saiola H., Naveri H., and Fyhrquist F. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. J. Pharmacol. Exp. Ther. 254 (1990) 641-645
321. Tomita K., Endou H., and Sakai F. Localization of kallikrein-like activity along a single nephron in rabbits. Pflugers Arch. 389 (1981) 91-95
322. Tomita K., Shiigai T., Shichiriki J., Andou R., Shinoda T., and Takeuchi J. Increased urinary kallikrein-like activity in the syndrome of inappropriate secretion of antidiuretic hormone. Nephron 35 (1983) 39-48
323. 3 H]-bradykinin in isolated nephron segments of the rabbit. Am. J. Physiol. 246 (1984) F732-F737
324. Tomita K., Shiigai T., Saito H., lino Y., and Takeuchi J. Increased urinary kallikrein-like activity during ADH-induced hyponatremia in rats. Hypertension 6 (1984) 511-518
325. Tomita K., Pisano J.J., and Knepper M.A. Control of sodium and potassium transport in the cortical collecting duct of the rat. J. Clin. Invest. 76 (1985) 132-136
326. Tomita K., Pisano J.J., Brug M.B., and Knepper M.A. Effects of vasopressin and bradykinin on anion transport by the rat cortical collecting duct. Evidence for an electroneutral sodium chloride transport pathway. J. Clin. Invest. 77 (1986) 136-141
327. Uchida Y., Tanaka K., Harada Y., Ueno A., and Katori M. Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy. Inflammation 7 (1983) 121-131
328. Uchida Y., and Katori M. Independent consumption of high and low molecular weight kininogens in vivo. Kinin IV, Part A (1986), Plenum Press, New York. 113-118
329. Uehara Y., Hirawa N., Kawabata Y., Suzuki T., Ohshima N., Oka K., Ikeda T., Goto A., Toyo-oka T., and Kizuki K. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24 (1994) 770-778
330. Uemura N., Vatner D.E., Shen Y.-T., Wang J., and Vatner S.F. Increased aladrenergic vascular sensitivity during development of hypertension in conscious dogs. Am. J. Physiol. 264 (1993) H1259-H1268
331. Ura N., Shimamoto K., Nakao T., Ogasawara A., Tanaka S., Mita T., Nishimiya T., and Iimura O. The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension. Clin. Exp. Hypertens. 5 (1985) 329-337
332. Ura N., Carretero O.A., and Erdoes E.G. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32 (1987) 507-513
333. Ura N., Shimamoto K., Satoh S., Kuroda S., Nomura N., Ohtomo Y., Masuda A., and Iimura O. Renal kininase I, kininase II and neutral endopeptidase 24.11 activities in patients with essential hypertension, primary aldosteronism and Cushing's syndrome. Hypertens. Res. 16 (1993) 253-258
334. Ura N., Shimamoto K., Kuroda S., Nomura N., Iwata M., Aoyama T., and Iimura O. The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats. Clin. Exp. Hypertens. 16 (1994) 799-808
335. Vio C.P., and Figueroa C.D. Subcellular localization of renal kallikrein by ultrastructural immunocytochemistry. Kidney Int. 28 (1985) 35-42
336. Vio C.P., and Figueroa C.D. Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int. 31 (1987) 1327-1334
337. Vio C.P., Figueroa C.D., and Caorsi I. Anatomical relationship between kallikrein- containing tubules and the juxtaglomerular apparatus in the human kidney. Am. J. Hypertens. 1 (1988) 269-271
338. Vogel R., and Werle E. Kallikrein inhibitors. Bradykinin, Kallidin and Kallikrein (1970), Springer-Verlag, New York. 213-249
339. Wang J., Xiong W., Yang S., Davis T., Chao J., and Chao J. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23 (1994) 236-243
340. Wang C., Chao L., and Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95 (1995) 1710-1716
341. Wang C., Chen Y.-P., Chao L., and Chao J. Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem. Biopbys. Res. Commun. 217 (1995) 113-122
342. Ward P.E., and Margolius H.S. Renal and urinary kallikrein. Bradykinin, Kallidin and Kallikrein. 25 (1979), Springer-Verlag, New York. 525-548 (Suppl. 5)
343. Watson S., and Girdlestone D. 1996 Receptor & Ion Channel Nomenclature Supplement. Trends Pharmacol. Sci. (1996)
344. Webster M.E., and Gilmore J.P. Influence of kallidin-10 on renal function. Am. J. Physiol. 206 (1964) 714-718
345. Weidmann P. Pathogenic and therapeutic relevance of cardiovascular pressor reactivity to norepinephrine in human hypertension. Clin. Exp. Hypertens. 11 Suppl. 5 (1989) 257-273
346. Widgren B.R., Herlitz H., Aurell M., Berglund G., Wikstrand J., and Andersson O.K. Increased systemic and renal vascular sensitivity to angiotensin II in normotensive men with positive family histories of hypertension. Am. J. Hypertens. 5 (1992) 167-174
347. Wiemer G., Fink E., Linz W., Hropot M., Scholkens B.E., and Wohlfart P. Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin. J. Pharmacol. Exp. Therap. 271 (1994) 1611-1615
348. Wilks S. Prolyl endopeptidase. Life Sci. 33 (1983) 2149-2157
349. Williams R.R., Hunt S.C., Hopkins P.N., Wu L.L., Hasstedt S.J., Berry T.D., Barlow G.K., Stults B.M., Schumacher M.C., Ludwig E.H., Elbein S.C., Wilson D.E., Lifton R.P., and Lalouel J.M. Genetic basis of familial dyslipidemia and hypertension: 15-years results from Utah. Am. J Hypertens. 6 (1993) 319S-327S
350. Wuepper K.D., Miller R.D., and Lacome M.-J. Flaujeac trait: Deficiency of human plasma kininogen. J. Clin. Invest. 56 (1975) 1663-1672
351. Xiong W., Chao L., and Chao J. Renal kallikrein mRNA localization by in situ hybridization. Kidney Int. 35 (1989) 1324-1329
352. Xiong W., Chao L., and Chao J. Muscle delivery of human kallikrein gene reduced blood pressure in hypertensive rats. II. Hypertension 25 (1995) 715-719
353. Yamada K., Hasunuma K., Shiina T., Ito K., Tamura Y., and Yoshida S. Interrelationship between kallikrein-kinins and arginine vasopressin in man. Clin. Sci. 76 (1989) 13-18
354. Yamasu A., Oh-ishi S., Hayashi I., Hayashi M., Yamaki K., Nakano T., and Sunahara N. Differentiation of kinin fractions in ureter urine and bladder urine of normal and kininogen-deficient rats. J. Pbarmacobiodyn. 12 (1989) 287-292
355. Yang T., Terada Y., Nonoguchi H., Tsujino M., Tomita K., and Marumo F. Distribution of kallikrein-binding protein mRNA in kidneys and difference between SHR and WKY rats. Am. J. Physiol. 267 (1994) F325-F330
356. Yoshida H., Mitarai T., Kawamura T., Kitajima T., Miyazaki Y., Nagasawa R., Kawaguchi Y., Kudo H., Ichikawa I., and Sakai O. Role of the deletion of polymorphism of the angiotensin-converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J. Clin. Invest. 96 (1995) 2162-2169
357. Zhou G.X., Chao L., and Chao J. Kallistatin: A novel human tissue kallikrein inhibitor. J. Biol. Chem. 267 (1992) 25873-25880
358. Zimmerman B.G., Raich P.C., Vavrek R.J., and Stewart J.M. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Circ. Res. 66 (1990) 242-248
359. Zinner S.H., Levy P.S., and Kass E.H. Familial aggregation of blood pressure in childhood. N. Engl. J. Med. 284 (1971) 401
360. Zinner S.H., Margolius H.S., Rosner B., Keiser H.R., and Rass E.H. Familial aggregation of urinary kallikrein concentration in childhood. Am. J. Epidemiol. 104 (1976) 124-132
361. Zinner S.H., Margolius H.S., Rosner B., and Kass E.H. Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight-year follow-up. Circulation 58 (1978) 908-915
362. Zschiederich H., Fleckenstein P., Geiger R., Fink E., Sinterhauf K., Philip T., Distler A., and Wolffe H.P. Urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension. Clin. Exp. Hypertens. 2 (1980) 693-708
363. 2 in the dog. Am. J. Physiol. 245 (1983) R329-R333